Amy L. Longenecker

Amy L. Longenecker

Auto-generated profile, based on publicly available information

Amy L. Longenecker

Department of Dermatology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
ASAndrea M. Schneider
Andrea M. Schneider
ZNZachary T. Nolan
Zachary T. Nolan
KBKalins Banerjee
Kalins Banerjee
APAllison R. Paine
Allison R. Paine
ZCZhaoyuan Cong
Zhaoyuan Cong
ANAmanda M. Nelson
Amanda M. Nelson

1 March 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ASAndrea M. Schneider
Andrea M. Schneider
LCLauren C. Cook
Lauren C. Cook
XZXiang Zhan
Xiang Zhan
KBKalins Banerjee
Kalins Banerjee
ZCZhaoyuan Cong
Zhaoyuan Cong
ANAmanda M. Nelson
Amanda M. Nelson

20 May 2019 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
ANAmanda M. Nelson
Amanda M. Nelson
ZCZhaoyuan Cong
Zhaoyuan Cong
SGSamantha L. Gettle
Samantha L. Gettle
ALAmy L. Longenecker
Amy L. Longenecker
MKMichal Kidacki
Michal Kidacki
FDFrederick W. Danby
Frederick W. Danby

31 March 2023 in Experimental Dermatology
Verified
Journal Article
Open access
ZNZachary T. Nolan
Zachary T. Nolan
KBKalins Banerjee
Kalins Banerjee
ZCZhaoyuan Cong
Zhaoyuan Cong
SGSamantha L. Gettle
Samantha L. Gettle
ALAmy L. Longenecker
Amy L. Longenecker
ANAmanda M. Nelson
Amanda M. Nelson
There are no drugs as effective as isotretinoin for acne. Deciphering the changes in the microbiome induced by isotretinoin in the pilosebaceous follicle of successfully treated patients can pave the way to identify novel therapeutic alternatives. We determined how the follicular microbiome changes with isotretinoin and identified which alterations correlate with a successful treatment response. Whole genome sequencing was done on casts from facial follicles of acne patients sampled before, during and after isotretinoin treatment. Alterations in the microbiome were assessed and correlated with treatment response at 20 weeks as defined as a 2‐grade improvement in global assessment score. We investigated the α‐diversity, β‐diversity, relative abundance of individual taxa, Cutibacterium acnes strain composition and bacterial metabolic profiles with a computational approach. We found that increased β‐diversity of the microbiome coincides with a successful treatment response to isotretinoin at 20 weeks. Isotretinoin selectively altered C. acnes strain diversity in SLST A and D clusters, with increased diversity in D1 strains correlating with a successful clinical response. Isotretinoin significantly decreased the prevalence of KEGG Ontology (KO) terms associated with four distinct metabolic pathways inferring that follicular microbes may have limited capacity for growth or survival following treatment. Importantly, these alterations in microbial composition or metabolic profiles were not observed in patients that failed to achieve a successful response at 20 weeks. Alternative approaches to recapitulate this shift in the balance of C. acnes strains and microbiome metabolic function within the follicle may be beneficial in the future treatment of acne.

21 December 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
SSStephanie L Schell
Stephanie L Schell
MSMackenzie L Sennett
Mackenzie L Sennett
RFRobert P Feehan
Robert P Feehan
TWTierney E Wallace
Tierney E Wallace
EMElizabeth C Meiszberg
Elizabeth C Meiszberg
ANAmanda M Nelson
Amanda M Nelson
Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no U.S. Food and Drug Administration-approved therapies for early-stage HS. Topical Janus kinase (JAK) inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signalling in HS lesions and the recent success of systemic JAKi for the treatment of moderate-to-severe HS. Objectives: To assess the clinical efficacy of ruxolitinib in a pilot cohort and to investigate the underlying biologic mechanisms associated with clinical response. Methods: This was a pilot single-site open-label prospective 24-week clinical trial of topical ruxolitinib (NCT04414514). Men and women with mild HS (Hurley stage I or II), with active inflammatory nodules, were recruited. All participants were observed for 8 weeks to monitor lesion counts (observational phase); active therapy (treatment phase) was then administered for 16 weeks. Topical ruxolitinib 1.5% cream was applied twice daily, covering the entirety of each HS-affected body site. Clinician- and patient-reported outcome measures were recorded throughout the study. Lesional skin punch biopsies were taken at the start and end of treatment for downstream mechanistic RNA sequencing and histological analyses. Results: Ten participants were enrolled in the study; four dropped out before the treatment phase of the trial. Six individuals with Hurley stage I (no tunnels) HS completed the study, five of whom successfully achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) through 16 weeks of therapy. In this interim analysis, differential gene expression and gene set enrichment analyses revealed reduced activation of JAK-dependent interferon, interleukin (IL)-6, IL-2 and epidermal growth factor receptor signalling, and antimicrobial and keratinocyte responses. In contrast, signatures of wound healing and lipid metabolism were increased following JAKi treatment, indicating a return to homeostasis. Histological analyses revealed that clinically responsive patients had significantly reduced epidermal and dermal inflammation. Affected inflammatory infiltrate included neutrophils, T cells and plasma cells, with the predominantly affected cell types specific to the patient. Conclusions: Collectively, the broad activity of topical ruxolitinib on inflammatory signalling processes resulted in promising efficacy, even with heterogeneity in baseline inflammation, in this pilot cohort. Importantly, topical treatment not only resolved epidermal inflammation, but also cleared deeper inflammatory infiltrate. The observed efficacy provides rationale to further investigate topical JAKi and other novel topical treatments in HS.

19 December 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MSMackenzie L. Sennett
Mackenzie L. Sennett
RFRobert P. Feehan
Robert P. Feehan
TWTierney E. Wallace
Tierney E. Wallace
SGSamantha L. Gettle
Samantha L. Gettle
ALAmy L. Longenecker
Amy L. Longenecker
ANAmanda M. Nelson
Amanda M. Nelson